Edition:
India

Indivior PLC (INDV.L)

INDV.L on London Stock Exchange

125.55GBp
18 Jan 2019
Change (% chg)

1.00 (+0.80%)
Prev Close
124.55
Open
124.40
Day's High
128.75
Day's Low
123.20
Volume
2,074,315
Avg. Vol
3,968,697
52-wk High
504.60
52-wk Low
75.48

Chart for

About

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue... (more)

Overall

Beta: --
Market Cap(Mil.): £2,498.61
Shares Outstanding(Mil.): 721.46
Dividend: --
Yield (%): --

Financials

  INDV.L Industry Sector
P/E (TTM): 48.23 30.48 33.71
EPS (TTM): 0.07 -- --
ROI: 25.75 14.98 14.48
ROE: -- 16.31 15.99

Indivior plans cheaper opioid addiction drug if rivals launch copycats

Indivior Plc said on Tuesday it could launch a cheaper version of its blockbuster opioid addiction treatment, Suboxone, if rivals release generic versions of the drug.

18 Dec 2018

Indivior plans cheaper opioid addiction drug if rivals launch copycats

Indivior Plc said on Tuesday it could launch a cheaper version of its blockbuster opioid addiction treatment, Suboxone, if rivals release generic versions of the drug.

18 Dec 2018

UPDATE 3-Indivior plans cheaper opioid addiction drug if rivals launch copycats

* Shares jump 17 pct after strategy update (Recasts lead, updates shares)

18 Dec 2018

Indivior to launch cheaper opioid addiction drug; maintains forecast

Dec 18 British drugmaker Indivior Plc said on Tuesday it would launch a cheaper version of its blockbuster opioid addiction treatment drug, while maintaining its full-year profit and revenue forecast.

18 Dec 2018

Indivior wins fresh hold on Dr. Reddy's Suboxone copy

Indivior Plc has secured another hold on the launch of a generic competitor to its best-selling opioid addiction drug in the United States, the London-listed company said on Wednesday.

12 Dec 2018

Indivior wins fresh hold on Dr. Reddy's Suboxone copy

Indivior Plc has secured another hold on the launch of a generic competitor to its best-selling opioid addiction drug in the United States, the London-listed company said on Wednesday.

12 Dec 2018

REFILE-UPDATE 1-Indivior wins fresh hold on Dr. Reddy's Suboxone copy

Dec 12 Indivior Plc has secured another hold on the launch of a generic competitor to its best-selling opioid addiction drug in the United States, the London-listed company said on Wednesday.

12 Dec 2018

Indivior says wins fresh hold on Suboxone copy

Dec 12 Indivior Plc said on Wednesday a U.S. court ruling had put a hold on Indian rival Dr. Reddy's Laboratories launching a generic competitor to the London-listed drugmaker's bestselling opioid addiction treatment.

12 Dec 2018

Indivior to discuss strategy, contingency plans on Dec. 18

Nov 27 Indivior Plc said it will discuss its strategy and contingency plans in a conference call on Dec. 18, after an U.S. court allowed rival Dr. Reddy's Laboratories Ltd to sell a copycat version of its blockbuster drug Suboxone.

27 Nov 2018

Indivior backs FY view, warns of generic rival hit; shares fall

Shares of drugmaker Indivior Plc fell as much as 10 percent on Wednesday, a day after the company lost a legal battle that will allow an Indian generic rival to sell a copycat version of its blockbuster film-based opioid addiction treatment.

21 Nov 2018

Earnings vs. Estimates